Currenlty, Smartpharm Therapeutics in the early stages of a DoD grant award to explore our technology's application toward a COVID19 prophylactic.• Responsible for R&D strategy, planning, and oversight. • Responsible for the sourcing and screening of Lipid Nanoparticle and Block polymer formulations.• Responsible for the design and screening of mRNA therapeutics.• Responsible for the design and screening of plasmid DNA therapeutics.• Developed screening assays of lead program for Gaucher Disease type I• Sourced and managed CROs for multiple projects.• Principal investigator for IACUC and ACURO protocols.• Managed partnerships and academic collaborations.

• Matrix role sourcing CROs, developing assays, and gene editing metrics to assess novel AAVs.• Delivered novel enzyme potency assay for lead program.• Delivered POC for gene editing in patient derived bronchial endothelial cells.• Delivered POC in select primary cell lines for novel AAV tropism.• Significant role in external BD partnership.• FACs analysis, sorting, cloning, and ddPCR of gene edited cell lines.

• Head of In Vitro Biology group managing 4 direct reports of a matrix team that screen therapeutic oligonucleotides for all RaNA projects.• Head of Optimization team responsible for design and testing of hit to lead oligonucleotides.• Established all of RaNA’s screening protocols and data analysis methods.• Project lead of HbF / β Thalassemia initiative. Directly worked with Ryzard Kole managing academic collaboration.• Managed numerous CRO’s to outsource antibody production, vector generation, oligonucleotide synthesis, compound formulation, and screening efforts. • Independently initiated and established academic collaborations to facilitate RaNA projects• Responsible nuclear fractionation, RNA isolation, and rRNA depletion for RNASeq.• Attended Cold Spring Harbors Genome Access Course • Attended EMBL conference on Epigenetic and Transcriptional Regulation Symposium Heidelberg Germany 2014

• Team leader of Endosomal escape assay development group. Prioritized goals, set team agendas and project timelines.• Project leader of COPD project with findings to be published in 2011. The project involved screening various kinase inhibitors and steroids in patient-derived clinical samples; investigated their roles in the immunological response of COPD patients.• Awarded 2 Individual Performance Awards for teamwork, leadership and collaboration.• Submitted 1st author manuscript for publication on the roles of kinases and microRNA in colorectal cancer.• Presented at internal Pfizer Kinase and RNAi symposiums and have 2 first authorship posters detailing work in Endosomal escape assay development and the development of a Therapeutic Nucleic Acid screen in Primary hepatocytes.• Active member of the Pfizer RNAi network and miRNA interest group.• Developed a therapeutic nucleic acid compound screen in primary hepatocytes that has led to the finding of 2 new lead molecules.• Developed a non-commercial ELISA to monitor reporter gene expression in preclinical studies.• Developed a high content screening assay in primary hepatocytes to evaluate oligonucleotides / siRNA uptake, mechanisms of entry and endosomal escape.• Screened siRNAs for mRNA and protein knockdown using bDNA and Bioplex, respectively.• Expert in the use of BioPlex 200, Agilent 1100 HPLC, Agilent BioAnalyzer, LiCor Blotting system, Zeiss LSM 510, Biomek Fx liquid handling system and high content screening (BD Pathway 855). Image analysis performed with CellProfiler, ImageJ and Metamorph. Utilized the FlexmiR platform, BioPlex Phosphoprotein and Cytokine assays and bDNA technology for a number of the above projects.

Lead Biologist on a Neuropeptide S (NPS) program. My responsibilities involved assay optimization and troubleshooting, CRO recruitment, and management, EC50, IC50, Schild data analysis and statistical interpretation for the selection of lead compounds.Presented data summaries to upper management and SAR team. Worked directly with modeling and chemistry team leads to identify leads and triage compounds for path forward.